Gadoxetic acid-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma
- PMID: 19457834
- DOI: 10.2214/AJR.08.1262
Gadoxetic acid-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma
Abstract
Objective: We compared the diagnostic performance of gadoxetic acid-enhanced MRI with that of triple-phase 16-, 40-, and 64-MDCT in the preoperative detection of hepatocellular carcinoma (HCC).
Subjects and methods: Sixty-two consecutively registered patients (54 men, eight women; age range, 31-67 years) with 83 HCCs underwent triple-phase (arterial, portal venous, equilibrium) CT at 16-, 40-, or 64-MDCT and gadoxetic acid-enhanced 3-T MRI. The diagnosis of HCC was established after surgical resection. Three observers independently and randomly reviewed the MR and CT images on a tumor-by-tumor basis. The diagnostic accuracy of these techniques in the detection of HCC was assessed with alternative free response receiver operating characteristic (ROC) analysis. Sensitivity, positive and negative predictive values, and sensitivity according to tumor size were evaluated.
Results: For each observer, the areas under the ROC curve were 0.971, 0.959, and 0.967 for MRI and 0.947, 0.950, and 0.943 for CT. The differences were not statistically significant between the two techniques for each observer (p > 0.05). The differences in sensitivity and positive and negative predictive values between the two techniques for each observer were not statistically significant (p > 0.05). Among 10 HCCs 1 cm in diameter or smaller, each of the observers detected seven tumors with MRI. With CT, one observer detected five, one observer detected four, and one observer detected three HCCs with no statistically significant difference (p > 0.05).
Conclusion: Gadoxetic acid-enhanced MRI and triple-phase MDCT have similar diagnostic performance in the preoperative detection of HCC, but MRI may be better than MDCT in the detection of HCC 1 cm in diameter or smaller.
Similar articles
-
Gadoxetic acid-enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (< or =2 cm in diameter) from arterial enhancing pseudolesions: special emphasis on hepatobiliary phase imaging.Invest Radiol. 2010 Feb;45(2):96-103. doi: 10.1097/RLI.0b013e3181c5faf7. Invest Radiol. 2010. PMID: 20057319
-
Hepatocellular carcinoma in patients with chronic liver disease: a comparison of gadoxetic acid-enhanced MRI and multiphasic MDCT.Clin Radiol. 2012 Feb;67(2):148-56. doi: 10.1016/j.crad.2011.08.011. Epub 2011 Sep 13. Clin Radiol. 2012. PMID: 21920517
-
Comparison of gadoxetic acid-enhanced MR imaging versus four-phase multi-detector row computed tomography in assessing tumor regression after radiofrequency ablation in subjects with hepatocellular carcinomas.J Vasc Interv Radiol. 2010 Mar;21(3):348-56. doi: 10.1016/j.jvir.2009.11.014. Epub 2010 Feb 8. J Vasc Interv Radiol. 2010. PMID: 20116285 Clinical Trial.
-
Hepatobiliary MR contrast agents in hypovascular hepatocellular carcinoma.J Magn Reson Imaging. 2015 Feb;41(2):251-65. doi: 10.1002/jmri.24712. Epub 2014 Aug 8. J Magn Reson Imaging. 2015. PMID: 25104398 Review.
-
Consensus report of the Fifth International Forum for Liver MRI.AJR Am J Roentgenol. 2013 Jul;201(1):97-107. doi: 10.2214/AJR.12.9491. AJR Am J Roentgenol. 2013. PMID: 23789662
Cited by
-
Assessment of arterial hypervascularity of hepatocellular carcinoma: comparison of contrast-enhanced US and gadoxetate disodium-enhanced MR imaging.Eur Radiol. 2012 Jun;22(6):1205-13. doi: 10.1007/s00330-011-2372-3. Epub 2012 Jan 24. Eur Radiol. 2012. PMID: 22270142
-
Risk of hypervascularization in small hypovascular hepatic nodules showing hypointense in the hepatobiliary phase of gadoxetic acid-enhanced MRI in patients with chronic liver disease.Jpn J Radiol. 2012 Nov;30(9):743-51. doi: 10.1007/s11604-012-0120-5. Epub 2012 Sep 22. Jpn J Radiol. 2012. PMID: 23001373
-
Gd-EOB-DTPA-enhanced magnetic resonance imaging combined with T1 mapping predicts the degree of differentiation in hepatocellular carcinoma.BMC Cancer. 2016 Aug 12;16:625. doi: 10.1186/s12885-016-2607-4. BMC Cancer. 2016. PMID: 27520833 Free PMC article.
-
Outcomes of follow-up CT for small (5-10-mm) arterially enhancing nodules in the liver and risk factors for developing hepatocellular carcinoma in a surveillance population.Eur Radiol. 2010 Oct;20(10):2397-404. doi: 10.1007/s00330-010-1810-y. Epub 2010 Jun 19. Eur Radiol. 2010. PMID: 20559837
-
Added value of hepatobiliary phase gadoxetic acid-enhanced MRI for diagnosing hepatocellular carcinoma in high-risk patients.World J Gastroenterol. 2013 Dec 7;19(45):8357-65. doi: 10.3748/wjg.v19.i45.8357. World J Gastroenterol. 2013. PMID: 24363528 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical